← Back to Search

Senolytic Drug

Fisetin for Coronavirus

Phase 2
Waitlist Available
Led By Paschalis Vergidis, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months

Summary

This trial will test whether Fisetin can help prevent the progression of coronavirus and its complications.

Who is the study for?
Adults aged 18+ with COVID-19 confirmed by a PCR test, especially those over 60 or aged 18-59 with conditions like obesity, diabetes, lung diseases (asthma/COPD), heart issues (past strokes or heart attacks), high blood pressure, history of smoking/vaping, or past chemotherapy/radiation. Must not be pregnant and willing to use contraception.
What is being tested?
The trial is testing Fisetin—a drug that might reduce inflammation and prevent worsening of coronavirus symptoms—against a placebo. Participants will randomly receive either Fisetin or an inactive substance to compare outcomes.
What are the potential side effects?
Specific side effects for Fisetin are not detailed here but may include typical drug reactions such as allergic responses, gastrointestinal discomforts, headaches, dizziness or other common medication-related side effects.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in oxygenation status
Serious Adverse Events
Secondary study objectives
CoV Severity Category

Side effects data

From 2023 Phase 1 & 2 trial • 75 Patients • NCT04210986
38%
Arthralgia
15%
Pain in Extremity
12%
Lab Findings
12%
Nausea
9%
Fatigue
9%
Back Pain
9%
Headache
6%
Muscle Cramp
6%
Flatulence
6%
Dry Mouth
6%
Rash Maculo-Papular
3%
Covid 19
3%
Bladder Perforation
3%
Neoplasms
3%
Rotator Cuff Injury
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Fisetin

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment GroupExperimental Treatment1 Intervention
Subjects will receive treatment drug Fisetin
Group II: Placebo GroupPlacebo Group1 Intervention
Subjects will receive placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fisetin
2016
Completed Phase 2
~250

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,339 Previous Clinical Trials
3,062,065 Total Patients Enrolled
Paschalis Vergidis, MDPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials
87 Total Patients Enrolled
James L Kirkland, MD, PhDPrincipal InvestigatorMayo Clinic
4 Previous Clinical Trials
155 Total Patients Enrolled
~0 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top